血清miR-374a在非小细胞肺癌中的表达及临床意义

Expression and clinical significance of serum miR-374a in non-small cell lung cancer

目的探讨microRNA-374a(miR-374a)在非小细胞肺癌患者血清中的表达及临床意义。方法采用实时荧光定量PCR(SYBgreen法)检测65例非小细胞肺癌(NSCLC)患者和70例健康人(健康对照组)血清中miR-374a的表达水平。结果 miR-374a在NSCLC患者血清中表达水平显著高于健康对照组(3.84±1.21 vs.1.09±0.16,P<0.05),并且其表达与临床TNM分期和淋巴结转移有关(P<0.05)。血清miR-374a在受试者工作特征曲线(ROC曲线)下面积(AUC)为0.927(95%CI:0.875~0.975)。当血清miR-374a临界值取1.615时,对NSCLC诊断的灵敏度为87.69%,特异度为97.14%。结论血清miR-374a有望成为一种新的生物标志物用于NSCLC的辅助诊断。

Objective To investigate the expression and clinical significance of serum miR-374a in non-small cell lung cancer （NSCLC）. Methods The quantitative real-time PCR was used to measure the serum level of miR-374a in 65 cases of NSCLC and 70 healthy subjects（healthy control group）. Results The serum miR-374a level in the patients with NSCLC was significantly higher than that in the healthy control group（3.84±1.21 vs. 1.09 ± 0.16, P〈0.05）. Moreover its expression was related with the lymph node metastasis and TNM stage （P〈0.05）. The area under ROC curve （AUC） yielded by miR-374a was 0. 927 （95%CI： 0. 875-0. 975）. When serum miR-374a critical value was 1. 615, the sensitivity and specificity of miR-374a for diagnosing NSCLC were 87.69% and 97.14% respectively. Conclusion Serum miR-374a level may be expected to be a novel biomarker and used for the auxiliary diagnosis of NSCLC.